Big pharmaceutical companies will have to tread very carefully if they try to limit supplies to low-cost markets in Europe in order to prevent their drugs being re-exported where they command higher prices, Europe's top court said yesterday.
The European Court of Justice said that if a dominant company refused to meet "ordinary" orders for medicinal products in order to stop "parallel exports", it was breaching EU competition law.
FT
No comments:
Post a Comment